The researchers of the study say their findings may aid the hematological community in determining the value of integrating gene expression profiles in contemporary prognostic models to better identify high-risk patients with a poor prognosis.
A proof-of-concept study suggests gene expression profiles (GEPs) of granulocytes may offer complementary prognostic information to current models of risk stratification for myelofibrosis (MF).
The researchers of the study say their findings may aid the hematological community in determining the value of integrating GEPs in contemporary prognostic models to better identify high-risk patients with poor prognoses.
They also note that future studies may prospectively validate their findings in an independent group of MF cases, which can help improve identification of patients with poorer prognoses who can benefit from clinical trials or allogeneic stem cell transplantation.
The GEPs of 144 patients were analyzed in the study, from which 201 survival-related transcripts emerged via a Cox-regression analysis. According to the researchers, they focused on granulocytes because they are an “easily accessible myeloid cell population that belongs to the neoplastic clone, unlike peripheral blood mononuclear cells that also contain lymphoid elements.”
The transcripts characterized patients who were at high risk of death, with these patients demonstrating both inferior overall survival (hazard ratio [HR] 4.736; 95% CI) and leukemia-free survival (HR 3.976; 95% CI) compared with patients characterized as low risk. Unsurprisingly, more pre-primary MF samples were characterized as low risk and more secondary MF samples were characterized as high risk.
High-risk patients also displayed clinical and molecular features typically associated with poor prognosis, like having high molecular risk mutations.
“Our results demonstrated that gene expression–based classification showed good agreement with contemporary prognostic models; indeed, the high-risk classification correlated with the presence of several detrimental features, such as advanced age, decreased hemoglobin (Hb) levels (<10 g/dL) and platelet count (<100 x 109/L), increased white blood cell count (>25 x 109/L), circulating blasts ≥1% and 2%, and the presence of constitutional symptoms and splenomegaly,” explained the researchers.
A large portion of high-risk patients harbored JAK2V617F mutations and there was an increased presence of homozygous mutations in this group. Meanwhile, low-risk patients more frequently harbored JAK2 heterozygosity.
Reference: Rontauroli S, Castellano S, Guglielmelli P, et al. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Adv. 2021;5(5):1452-1462. doi:10.1182/bloodadvances.2020003614
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen